Sanofi ADR (SNY)vsSociedad Quimica y Minera de Chile SA ADR B (SQM)
SNY
Sanofi ADR
$43.31
+0.30%
HEALTHCARE · Cap: $103.45B
SQM
Sociedad Quimica y Minera de Chile SA ADR B
$91.60
-1.99%
BASIC MATERIALS · Cap: $26.16B
Smart Verdict
WallStSmart Research — data-driven comparison
Sanofi ADR generates 935% more annual revenue ($47.35B vs $4.58B). SNY leads profitability with a 16.0% profit margin vs 12.9%. SQM appears more attractively valued with a PEG of 0.60. SQM earns a higher WallStSmart Score of 66/100 (B-).
SNY
Buy51
out of 100
Grade: C-
SQM
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+25.0%
Fair Value
$62.70
Current Price
$43.31
$19.39 discount
Margin of Safety
+9.0%
Fair Value
$82.67
Current Price
$91.60
$8.93 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Large-cap with strong market position
Strong operational efficiency at 20.0%
Generating 1.7B in free cash flow
Earnings expanding 52.3% YoY
Growing faster than its price suggests
Strong operational efficiency at 28.3%
Revenue surging 23.3% year-over-year
Areas to Watch
ROE of 6.6% — below average capital efficiency
Expensive relative to growth rate
Earnings declined 11.7%
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : SNY
The strongest argument for SNY centers on Price/Book, Market Cap, Operating Margin. Profitability is solid with margins at 16.0% and operating margin at 20.0%.
Bull Case : SQM
The strongest argument for SQM centers on EPS Growth, PEG Ratio, Operating Margin. Revenue growth of 23.3% demonstrates continued momentum. PEG of 0.60 suggests the stock is reasonably priced for its growth.
Bear Case : SNY
The primary concerns for SNY are Return on Equity, PEG Ratio, EPS Growth.
Bear Case : SQM
The primary concerns for SQM are P/E Ratio. A P/E of 44.5x leaves little room for execution misses.
Key Dynamics to Monitor
SNY profiles as a mature stock while SQM is a growth play — different risk/reward profiles.
SQM carries more volatility with a beta of 1.03 — expect wider price swings.
SQM is growing revenue faster at 23.3% — sustainability is the question.
SNY generates stronger free cash flow (1.7B), providing more financial flexibility.
Bottom Line
SQM scores higher overall (66/100 vs 51/100) and 23.3% revenue growth. SNY offers better value entry with a 25.0% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Sanofi ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.
Sociedad Quimica y Minera de Chile SA ADR B
BASIC MATERIALS · SPECIALTY CHEMICALS · USA
Sociedad Qumica y Minera de Chile SA produces and distributes specialty plant nutrients, iodine and its derivatives, lithium and its derivatives, potassium chloride and sulfate, industrial chemicals and other products and services worldwide. The company is headquartered in Santiago, Chile.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?